Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors

被引：0
|
作者：
Vayda Schüttke
Cathrin Kusiek
Susanne Fuessel
Christian Thomas
Bjoern Thorben Buerk
Kati Erdmann
机构：
[1] Technische Universität Dresden,Department of Urology
[2] Faculty of Medicine and University Hospital Carl Gustav Carus,undefined
[3] German Cancer Consortium (DKTK),undefined
[4] Partner Site Dresden,undefined
[5] Dresden and German Cancer Research Center (DKFZ),undefined
来源：
Clinical and Translational Oncology | 2024年 / 26卷
关键词：
Biomarker; CRP kinetics; Immunotherapy; Metastatic renal cell carcinoma; Prognosis; Tyrosine kinase inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1117 / 1128
页数：11
相关论文
共 50 条
  • [1] Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors
    Schuettke, Vayda
    Kusiek, Cathrin
    Fuessel, Susanne
    Thomas, Christian
    Buerk, Bjoern Thorben
    Erdmann, Kati
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (05): : 1117 - 1128
  • [2] Early kinetics of C-reactive protein predicts oncological outcome of patients with metastatic renal cell carcinoma under first-line therapy with immune checkpoint inhibitors
    Schuettke, V
    Kusiek, C.
    Mehralivand, S.
    Buerk, B. T.
    Thomas, C.
    Fuessel, S.
    Erdmann, K.
    EUROPEAN UROLOGY, 2023, 83
  • [3] Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer
    Aragon-Ching, Jeanny B.
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (11) : 767 - 770
  • [4] Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma
    Saito, Kazutaka
    Tatokoro, Manabu
    Fujii, Yasuhisa
    Iimura, Yasumasa
    Koga, Fumitaka
    Kawakami, Satoru
    Kihara, Kazunori
    EUROPEAN UROLOGY, 2009, 55 (05) : 1145 - 1153
  • [5] A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
    Jo, Hyunji
    Hong, Joohyun
    Kim, Hongsik
    Kim, Hye Ryeon
    Kwon, Ghee Young
    Kang, Kyung A.
    Park, Sung Yoon
    Kim, Chan Kyo
    Park, Byung Kwan
    Chung, Jae Hoon
    Song, Wan
    Kang, Minyong
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Park, Se Hoon
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
    Boccaccino, A.
    Frapoli, M.
    Rossini, D.
    Salvatore, L.
    Passardi, A.
    Papiani, G.
    Valsecchi, A. A.
    Puccini, A.
    Massaro, G.
    Santucci, S.
    Guidolin, A.
    Spring, A.
    Romagnani, E.
    Tamberi, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S448 - S448
  • [7] Real-world data in the era of immune checkpoint inhibitors (ICIs): Cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Fu-Ming, C.
    Hsieh, C-Y.
    Wang, T-H.
    Tsai, M-H.
    Hua, C-H.
    Tang, C-H.
    Hsieh, C-H.
    Lien, M-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S667 - S667
  • [8] Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
    Chakiryan, Nicholas H.
    Jiang, Da David
    Gillis, Kyle A.
    Green, Elizabeth
    Hajiran, Ali
    Hugar, Lee
    Zemp, Logan
    Zhang, Jingsong
    Jain, Rohit K.
    Chahoud, Jad
    Spiess, Philippe E.
    Sexton, Wade
    Gilbert, Scott M.
    Manley, Brandon J.
    JAMA NETWORK OPEN, 2021, 4 (05) : E2111329
  • [9] Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab
    Markus Haas
    Alexander Lein
    Thorsten Fuereder
    Julia Schnoell
    Faris F. Brkic
    David T. Liu
    Lorenz Kadletz-Wanke
    Gregor Heiduschka
    Bernhard J. Jank
    Investigational New Drugs, 2023, 41 : 727 - 736
  • [10] Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab
    Haas, Markus
    Lein, Alexander
    Fuereder, Thorsten
    Schnoell, Julia
    Brkic, Faris F. F.
    Liu, David T. T.
    Kadletz-Wanke, Lorenz
    Heiduschka, Gregor
    Jank, Bernhard J. J.
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 727 - 736
12345